Oncology (Williston Park). 2020 Jul 15;34(7):254.
Frontline treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer (NSCLC) and tumor PD-L1 expression greater than 1% or less than 1%, according to updated results from part 1 of the phase 3 CheckMate 227 (NCT02477826)trial presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
根据在 2020 年美国临床肿瘤学会虚拟科学计划会议上展示的 CheckMate 227（NCT02477826）三期临床试验第 1 部分的更新结果，与化疗相比，纳武利尤单抗（Opdivo）联合易普利姆玛（Yervoy）一线治疗可使肿瘤 PD-L1 表达大于 1%或小于 1%的晚期非小细胞肺癌（NSCLC）患者获得持久和长期疗效。
